Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Exocrine Pancreatic Insufficiency 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × Pancrelipase × Clear all
NCT05642962 2026-02-25

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02985801 2021-03-15

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Mayo Clinic

Phase 1/2 Terminated
16 enrolled 5 charts
Gastrointestinal

Exocrine Pancreatic Insufficiency, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡